Claritin-D 24 Hour Review Documents Show Friction Between Schering & FDA
Executive Summary
The negotiations between FDA and Schering-Plough in 1998 over the approval of a new formulation of Claritin-D 24 Hour illustrate the history of friction between agency officials and company management.
You may also be interested in...
Schering Compliance Team Will Report To CEO Following COO Resignation
Schering-Plough's compliance team for resolving FDA's Good Manufacturing Practices concerns with the company will report directly to CEO Richard Kogan following the resignation of President & Chief Operating Officer Raul Cesan.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials